Understanding and Overcoming Drug Resistance in Medulloblastoma
Transporters and Medulloblastoma
This work explores new ways to help children with medulloblastoma by making their chemotherapy more effective against the tumor.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Jude Children's Research Hospital NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-11045634 on NIH RePORTER |
What this research studies
Medulloblastoma, a common and serious brain cancer in children, is often hard to treat because chemotherapy drugs struggle to reach the tumor due to natural barriers in the brain. This project focuses on a specific barrier protein called ABCG2, which is highly active in aggressive forms of medulloblastoma and pushes chemotherapy drugs out of tumor cells. Researchers have found a new way to block ABCG2 by removing it from the cell surface, which could allow more chemotherapy to reach the cancer. This approach aims to improve how well current treatments work for children facing this challenging disease.
Who could benefit from this research
Good fit: This research is primarily focused on understanding and treating medulloblastoma, especially the aggressive Group 3 subtype, which affects children and young adults.
Not a fit: Patients with other types of cancer or those whose medulloblastoma does not involve the ABCG2 transporter may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to more effective chemotherapy treatments for children with medulloblastoma, potentially improving their survival and quality of life.
How similar studies have performed: While the concept of targeting drug transporters is known, this specific approach of promoting ABCG2 membrane retrieval with a novel inhibitor appears to be a new and promising strategy.
Where this research is happening
Memphis, United States
- St. Jude Children's Research Hospital — Memphis, United States (Active)
Researchers
- Principal investigator: Schuetz, John D — St. Jude Children's Research Hospital
- Study coordinator: Schuetz, John D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.